MedPath

Accuracy of MRI versus CT iMAGing to assess resectability following FOLFIRINOX for locally advancEd pancreatic cancer (IMAGE)

Completed
Conditions
pancreatic cancer
pancreatic carcinoma
10017991
Registration Number
NL-OMON43456
Lead Sponsor
Academisch Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

Patients with locally advanced pancreatic cancer, without distant metastases, after 2 months of FOLFIRINOX chemotherapy undergoing explorative laparotomy

Exclusion Criteria

Contra-indications for MRI

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Primary outcome measure: correct assessment of tumor resectability according to<br /><br>DWI MRI, compared to standard CT. </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Active tumor size on MRI and CT will be compared, and in patients receiving<br /><br>resection also compared to the active tumor size in the resected pathology<br /><br>specimen. </p><br>
© Copyright 2025. All Rights Reserved by MedPath